BACKGROUND: For a prognostic model to be used to guide treatment decisions, predictions should represent a patient’s outcome risk if they were to remain untreated. Clinical data used for model development typically include some individuals who were treated during follow-up. Ignoring this can lead to a model that underestimates the true untreated outcome risk.
OBJECTIVES: To compare methods to account for treatment use during follow-up when developing a prognostic model.
METHODS: A prognostic (Cox) model to predict 5-year mortality risk without using selective beta-blockers was developed using the electronic health record data of 1905 patients (585 deaths). We compared 5 methods to account for selective-beta blocker use during follow-up: (i) excluding treated individuals, (ii) censoring treated individuals, (iii) inverse probability of censoring weighting after censoring treated individuals, (iv) including treatment as a binary covariate in the model and (v) including treatment use as a time-varying covariate in the model. The comparisons were repeated in a highly-treated patient subset and with a simplified prognostic model.
RESULTS: 324 (17%) patients began using selective beta-blockers during follow-up. The coefficients of the prediction models varied according to each modelling method. Excluding treated individuals resulted in a model that provided, on average, slightly higher predictions compared to a model that ignored treatment. However, these differences did not translate to substantial differences in predictive performance (c-statistic, calibration slope, Brier score) in any of the analyses.
CONCLUSION: Treatment hardly affected predictive performance in our case study. Despite theoretical advantages of certain methods to account for treatment use, in practice the actual benefit of applying these methods may be small. Further case studies and simulations are needed to investigate when it is necessary to take into account the effect of treatment when developing a prognostic model.